scholarly journals Effect of Probiotic Supplementation along with Calorie Restriction on Metabolic Endotoxemia, and Inflammation Markers in Coronary Artery Disease Patients: A Double Blind Placebo Controlled Randomized Clinical Trial

2020 ◽  
Author(s):  
jalal moludi ◽  
Hossein Samadi Kafil ◽  
Pourya Gholizadeh ◽  
Mohammad Alizadeh ◽  
Hamed Jafari Vayghyan
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Lactobacillus Rhamnosus ◽  
Serum Levels ◽  
Interleukin 10 ◽  
Probiotic Supplementation ◽  
Related Factors ◽  
Double Blind ◽  
Artery Disease ◽  
Metabolic Endotoxemia

Abstract Purpose: Alterations in the gut microbiome (dysbiosis) has been associated with increased microbial translocation, leading to chronic inflammation in coronary artery disease (CAD). It has been proposed that modulation of gut microbiota by probiotic might modify metabolic endotoxemia. Therefore, the purpose of this study was to examine the effects of Lactobacillus rhamnosus GG (LGG) on metabolic endotoxemia, and marker of inflammation in CAD participants. Methods: This study was a 12-weeks randomized, double-blind, and intervention on 44 patients with CAD. Patients were randomly allocated to receive either one LGG capsule 1.6 ×109 colony-forming unit (CFU) or the placebo capsules for 12 weeks. In addition, all the participants were also prescribed a calorie-restricted diet. Serum levels of interleukin-1β (IL-1β), Toll-like receptor 4 (TLR4), interleukin-10 (IL-10), and lipopolysaccharide (LPS), were assessed before and after the intervention. Results: A significant decrease in IL1-Beta concentration (-1.88 ± 2.25, vs. 0.56 ± 1.58 mmol/L, P=0.027), and LPS levels (-5.20 ±2.70 vs. 2.96+ 5.27 mg/L, P=0.016), was observed after the probiotic supplementation compared with the placebo. Participants who had ≥2.5 kg weight loss showed significantly improved cardiovascular-related factors, compared to patients with <2.5 kg weight reduction, regardless of the supplement they took.Conclusion: These data provide preliminary evidence that probiotic supplementation has beneficial effects on metabolic endotoxemia, and mega inflammation in participants with CAD.

scholarly journals Effect of probiotic supplementation along with calorie restriction on metabolic endotoxemia, and inflammation markers in coronary artery disease patients: a double blind placebo controlled randomized clinical trial

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Jalal Moludi ◽  
Hossein Samadi Kafil ◽  
Shaimaa A. Qaisar ◽  
Pourya Gholizadeh ◽  
Mohammad Alizadeh ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Lactobacillus Rhamnosus ◽  
Serum Levels ◽  
Interleukin 10 ◽  
Probiotic Supplementation ◽  
Related Factors ◽  
Double Blind ◽  
Artery Disease ◽  
Metabolic Endotoxemia

Abstract Purpose Alterations in the gut microbiome (dysbiosis) has been associated with increased microbial translocation, leading to chronic inflammation in coronary artery disease (CAD). It has been proposed that modulation of gut microbiota by probiotic might modify metabolic endotoxemia. Therefore, the purpose of this study was to examine the effects of Lactobacillus rhamnosus GG (LGG) on endotoxin level, and biomarkers of inflammation in CAD participants. Methods This study was a 12-weeks randomized, double-blind, and intervention on 44 patients with CAD. Patients were randomly allocated to receive either one LGG capsule 1.6 × 109 colony-forming unit (CFU) or the placebo capsules for 12 weeks. In addition, all the participants were also prescribed a calorie-restricted diet. Serum levels of interleukin-1β (IL-1β), Toll-like receptor 4 (TLR4), interleukin-10 (IL-10), and lipopolysaccharide (LPS), were assessed before and after the intervention. Results A significant decrease in IL1-Beta concentration (− 1.88 ± 2.25, vs. 0.50 ± 1.58 mmol/L, P = 0.027), and LPS levels (− 5.88 ± 2.70 vs. 2.96+ 5.27 mg/L, P = 0.016), was observed after the probiotic supplementation compared with the placebo. Participants who had ≥2.5 kg weight loss showed significantly improved cardiovascular-related factors, compared to patients with < 2.5 kg weight reduction, regardless of the supplement they took. Conclusion These data provide preliminary evidence that probiotic supplementation has beneficial effects on metabolic endotoxemia, and mega inflammation in participants with CAD.

scholarly journals Effect of Probiotic Supplementation along with Calorie Restriction on Metabolic Endotoxemia, and Inflammation Markers in Coronary Artery Disease Patients: A Double Blind Placebo Controlled Randomized Clinical Trial

2021 ◽  
Author(s):  
jalal moludi ◽  
Hossein Samadi Kafil ◽  
Shaimaa A. Qaisar ◽  
Pourya Gholizadeh ◽  
Mohammad Alizadeh ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Lactobacillus Rhamnosus ◽  
Serum Levels ◽  
Interleukin 10 ◽  
Probiotic Supplementation ◽  
Related Factors ◽  
Double Blind ◽  
Artery Disease ◽  
Metabolic Endotoxemia

Abstract Purpose: Alterations in the gut microbiome (dysbiosis) has been associated with increased microbial translocation, leading to chronic inflammation in coronary artery disease (CAD). It has been proposed that modulation of gut microbiota by probiotic might modify metabolic endotoxemia. Therefore, the purpose of this study was to examine the effects of Lactobacillus rhamnosus GG (LGG) on endotoxin level, and biomarkers of inflammation in CAD participants. Methods: This study was a 12-weeks randomized, double-blind, and intervention on 44 patients with CAD. Patients were randomly allocated to receive either one LGG capsule 1.6 ×109 colony-forming unit (CFU) or the placebo capsules for 12 weeks. In addition, all the participants were also prescribed a calorie-restricted diet. Serum levels of interleukin-1β (IL-1β), Toll-like receptor 4 (TLR4), interleukin-10 (IL-10), and lipopolysaccharide (LPS), were assessed before and after the intervention. Results: A significant decrease in IL1-Beta concentration (-1.88 ± 2.25, vs. 0.56 ± 1.58 mmol/L, P=0.027), and LPS levels (-5.20 ±2.70 vs. 2.96+ 5.27 mg/L, P=0.016), was observed after the probiotic supplementation compared with the placebo. Participants who had ≥2.5 kg weight loss showed significantly improved cardiovascular-related factors, compared to patients with <2.5 kg weight reduction, regardless of the supplement they took.Conclusion: These data provide preliminary evidence that probiotic supplementation has beneficial effects on metabolic endotoxemia, and mega inflammation in participants with CAD.

scholarly journals Effect of Probiotic Supplementation Along With Calorie Restriction on Metabolic Endotoxemia, and Mega Inflammation in Coronary Artery Disease Patients: A Double Blind Placebo Controlled Randomized Clinical Trial

2020 ◽  
Author(s):  
jalal moludi ◽  
Hossein Samadi Kafil ◽  
Pourya Gholizadeh ◽  
Mohammad Alizadeh ◽  
Hamed Jafari Vayghyan
Keyword(s):  
Lactobacillus Rhamnosus ◽  
Serum Levels ◽  
Interleukin 10 ◽  
Preliminary Evidence ◽  
Probiotic Supplementation ◽  
Double Blind ◽  
Beneficial Effects ◽  
Before And After ◽  
Artery Disease ◽  
Metabolic Endotoxemia

Abstract Purpose: Dysbiosis has been associated with increased microbial translocation, leading to chronic inflammation in cardiovascular diseases (CVD). It has been proposed that modulation of gut microbiota by probiotic might modify metabolic endotoxemia. Therefore, the purpose of this study was to examine the effects of Lactobacillus rhamnosus GG (LGG) on metabolic endotoxemia, and marker of inflammation in CVD subjects. Methods: This study was a 12-weeks randomized, double-blind, and intervention on 44 patients with CVD. Patients were randomly allocated to receive either one LGG capsule 1.6 ×109 colony-forming unit (CFU) or the placebo capsules for 12 weeks. Serum levels of interleukin-1β (IL-1β), Toll-like receptor 4 (TLR4), interleukin-10 (IL-10), and lipopolysaccharide (LPS), were assessed before and after the intervention. Results: A significant decrease in IL1-Beta concentration (-1.88 ± 2.25, vs. 0.56 ± 1.58 mmol/L, P=0.027), and LPS levels (-5.20 ±2.70 vs. 2.96+ 5.27 mg/L, P=0.016), was observed after the probiotic supplementation compared with the placebo. Subjects who had ≥2.5 kg weight loss showed significantly improved in some variables, compared to patients with <2.5 kg weight reduction, regardless of the supplement they receive.Conclusion: These data provide preliminary evidence that probiotic supplementation has beneficial effects on metabolic endotoxemia, and mega inflammation in subjects with CVD.

scholarly journals Effect of Probiotic Supplementation along with Calorie Restriction on Metabolic Endotoxemia, Trimethylamine-N-Oxide, Inflammation, Metabolic Factors, and Gut Microbiota Profile in Coronary Artery Disease Patients: A Double Blind Placebo Controlled Randomized Clinical Trial

2020 ◽  
Author(s):  
Jalal Moludi ◽  
Hossein Samadi Kafil ◽  
Pouria Gholizadeh ◽  
Mohammad Alizadeh
Keyword(s):  
Gut Microbiota ◽  
Intervention Group ◽  
Lactobacillus Rhamnosus ◽  
Serum Levels ◽  
Interleukin 10 ◽  
Preliminary Evidence ◽  
Probiotic Supplementation ◽  
Double Blind ◽  
Beneficial Effects ◽  
Metabolic Endotoxemia

Abstract Background Dysbiosis has been associated to increased microbial translocation, leading to chronic inflammation in cardiovascular diseases (CVD). It has been proposed that modulation of gut microbiota by probiotic might modify metabolic endotoxemia. Therefore, the purpose of this study was to examine the effects of Lactobacillus rhamnosus GG (LGG) on metabolic endotoxemia, Trimethylamine-N-oxide (TMAO) and gut microbiota profiles in CVD subjects.Methods A 12-week randomized, double-blind, intervention on 44 patients with CVD. Patients were randomly allocated to receive either one LGG capsules 1.6 ×10 9 colony-forming unit (CFU) or the placebo capsules for 12 weeks. Gut microbiota profile and serum levels of interleukin‐1β (IL‐1β), Toll‐like receptor 4(TLR4), interleukin‐10(IL‐10), lipopolysaccharide(LPS), and TMAO were assessed before and after the intervention.Results A significant decrease in IL1-Beta concentration(-1.88 ± 2.25, vs. 0.56 ± 1.58 mmol/L, P=0.027), LPS levels(-5.20 ±2.70 vs. 2.96+ 5.27 mg/L, P=0.016), and TMAO levels (-19.34±20.40 vs. -6.45±7.7 mmol/L, P=0.043) was observed after the probiotic supplementation compared with the placebo. L. rhamnosus statically increased in intervention group while Bacteroidetes non - significantly increased in both groups. Subjects who had ≥2.5 kg weight loss showed significantly improved in some variables, compared to patients with <2.5 kg weight reduction, regardless of the supplement they receive. Regression analysis revealed that baseline TMAO, changes of protein intakes and IL1-Beta predicted 58% of the final TMAO levels.Conclusion : These data provide preliminary evidence that probiotic supplementation has beneficial effects on depressive symptoms, metabolic endotoxemia, TMAO, and gut microbiota profile in subjects with CVD.

scholarly journals Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease

2004 ◽  
Vol 44 (1) ◽  
pp. 44-49 ◽  
Author(s):  
Stephan Fichtlscherer ◽  
Susanne Breuer ◽  
Christopher Heeschen ◽  
Stefanie Dimmeler ◽  
Andreas M Zeiher
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Serum Levels ◽  
Interleukin 10 ◽  
Artery Disease

Osteoprotegerin and Osteopontin Serum Levels are Associated with Vascular Function and Inflammation in Coronary Artery Disease Patients

2020 ◽  
Vol 18 (5) ◽  
pp. 523-530 ◽  
Author(s):  
Konstantinos Maniatis ◽  
Gerasimos Siasos ◽  
Evangelos Oikonomou ◽  
Manolis Vavuranakis ◽  
Marina Zaromytidou ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Endothelial Function ◽  
Vascular Function ◽  
Serum Levels ◽  
Atherosclerosis Progression ◽  
Control Subjects ◽  
Significant Difference ◽  
Artery Disease ◽  
Stable Cad

Background: Osteoprotegerin and osteopontin have recently emerged as key factors in both vascular remodelling and atherosclerosis progression. Interleukin-6 (IL-6) is an inflammatory cytokine with a key role in atherosclerosis. The relationship of osteoprotegerin, osteopontin, and IL-6 serum levels with endothelial function and arterial stiffness was evaluated in patients with coronary artery disease (CAD). Methods: We enrolled 219 patients with stable CAD and 112 control subjects. Osteoprotegerin, osteopontin and IL-6 serum levels were measured using an ELISA assay. Endothelial function was evaluated by flow-mediated dilation (FMD) in the brachial artery and carotid-femoral pulse wave velocity (PWV) was measured as an index of aortic stiffness. Results: There was no significant difference between control subjects and CAD patients according to age and sex. Compared with control subjects, CAD patients had significantly impaired FMD (p<0.001) and increased PWV (p=0.009). CAD patients also had significantly higher levels of osteoprotegerin (p<0.001), osteopontin (p<0.001) and IL-6 (p=0.03), compared with control subjects. Moreover, IL-6 levels were correlated with osteoprotegerin (r=0.17, p=0.01) and osteopontin (r=0.30, p<0.001) levels. FMD was correlated with osteoprotegerin levels independent of possible confounders [b coefficient= - 0.79, 95% CI (-1.54, -0.05), p=0.04]. Conclusion: CAD patients have increased osteoprotegerin, osteopontin and IL-6 levels. Moreover, there is a consistent association between osteoprotegerin and osteopontin serum levels, vascular function and inflammation in CAD patients. These findings suggest another possible mechanism linking osteoprotegerin and osteopontin serum levels with CAD progression through arterial wall stiffening and inflammation.

scholarly journals Implications of cardiac markers in risk-stratification and management for COVID-19 patients

Critical Care ◽  
2021 ◽  
Vol 25 (1) ◽  
Author(s):  
Pengping Li ◽  
Wei Wu ◽  
Tingting Zhang ◽  
Ziyu Wang ◽  
Jie Li ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Risk Stratification ◽  
Rna Sequencing ◽  
High Mortality ◽  
Admission Rate ◽  
Serum Levels ◽  
Receptor Expression ◽  
Cardiac Markers ◽  
Artery Disease

Abstract Background COVID-19 has resulted in high mortality worldwide. Information regarding cardiac markers for precise risk-stratification is limited. We aim to discover sensitive and reliable early-warning biomarkers for optimizing management and improving the prognosis of COVID-19 patients. Methods A total of 2954 consecutive COVID-19 patients who were receiving treatment from the Wuhan Huoshenshan Hospital in China from February 4 to April 10 were included in this retrospective cohort. Serum levels of cardiac markers were collected after admission. Coronary artery disease diagnosis and survival status were recorded. Single-cell RNA-sequencing and bulk RNA-sequencing from different cohorts of non-COVID-19 were performed to analyze SARS-CoV-2 receptor expression. Results Among 2954 COVID-19 patients in the analysis, the median age was 60 years (50–68 years), 1461 (49.5%) were female, and 1515 (51.3%) were severe/critical. Compared to mild/moderate (1439, 48.7%) patients, severe/critical patients showed significantly higher levels of cardiac markers within the first week after admission. In severe/critical COVID-19 patients, those with abnormal serum levels of BNP (42 [24.6%] vs 7 [1.1%]), hs-TNI (38 [48.1%] vs 6 [1.0%]), α- HBDH (55 [10.4%] vs 2 [0.2%]), CK-MB (45 [36.3%] vs 12 [0.9%]), and LDH (56 [12.5%] vs 1 [0.1%]) had a significantly higher mortality rate compared to patients with normal levels. The same trend was observed in the ICU admission rate. Severe/critical COVID-19 patients with pre-existing coronary artery disease (165/1,155 [10.9%]) had more cases of BNP (52 [46.5%] vs 119 [16.5%]), hs-TNI (24 [26.7%] vs 9.6 [%], α- HBDH (86 [55.5%] vs 443 [34.4%]), CK-MB (27 [17.4%] vs 97 [7.5%]), and LDH (65 [41.9%] vs 382 [29.7%]), when compared with those without coronary artery disease. There was enhanced SARS-CoV-2 receptor expression in coronary artery disease compared with healthy controls. From regression analysis, patients with five elevated cardiac markers were at a higher risk of death (hazards ratio 3.4 [95% CI 2.4–4.8]). Conclusions COVID-19 patients with pre-existing coronary artery disease represented a higher abnormal percentage of cardiac markers, accompanied by high mortality and ICU admission rate. BNP together with hs-TNI, α- HBDH, CK-MB and LDH act as a prognostic biomarker in COVID-19 patients with or without pre-existing coronary artery disease.

Sign in / Sign up

Export Citation Format

Share Document